

Powered by CARB-X Projects formerly in the Pipeline

Sponsor	Product	Novelty			Description	Priority		Development Stage			
		New Abx Class	New Non-traditional Product	New Target		CDC	WHO	Hit to Lead	Lead Optimization	Pre-Clinical	Phase I
Achaogen	AKAO-LpxC	✓		✓	LpxC inhibitor	✓	✓	<i>P. aeruginosa</i>			
Redx Pharma	NBTI	✓			Dual-acting topoisomerase inhibitor	✓	✓	<i>Acinetobacter + P. aeruginosa + Enterobacteriaceae</i>			

Sponsor	Type	Technology	Description			
			Feasibility Demonstration	Optimization and Preparation for Development	Product Development	System Integration and
MicrobeDx	Near care Dx	CD based microfluidics	Urinary Tract Infection			